Navigation Links
AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
Date:7/17/2009

RESEARCH TRIANGLE PARK, N.C., July 17 /PRNewswire/ -- AlphaVax, Inc. announced today that it has completed process development and preclinical immunogenicity studies of its H1N1 (swine) influenza vaccine and will manufacture clinical trial material by the end of the month. This vaccine has shown good production yields as well as excellent immunogenicity, even after just a single inoculation.

"Our vaccine platform provides several potential advantages over other influenza vaccine approaches in that vaccines can be rapidly constructed and tested, and are produced in cell culture systems rather than eggs. In addition, our vaccines do not require the use of an adjuvant, and they raise not only strong antibody responses but robust cellular responses, both of which could be important in the face of a developing pandemic where there are several variant virus forms circulating," said Jonathan Smith, AlphaVax's Chief Scientific Officer.

The studies performed at AlphaVax utilized the California 04/2009 HA sequence obtained from the WHO GISAID database on April 25th. Mice inoculated with the AlphaVax H1N1 vaccine showed strong dose-dependent hemagglutination inhibition ("HI") antibody responses. After just a single dose of the H1N1 vaccine, all vaccinated animals developed HI antibody levels considered to be protective. These responses were boosted approximately 8-fold by a second dose given three weeks later. Responses measured by ELISA and ELISPOT assays, which assess antibody and T cell responses, respectively, mirrored the HI responses. The design of future clinical trials of this vaccine will be based on two previous successful influenza vaccine trials run by AlphaVax, one carried out in healthy young adults and the other in an elderly population.

According to Andrew Graham, AlphaVax's Vice President for Development and Technical Operations, "AlphaVax will begin GMP-compliant manufacturing of this vaccine for clinical testing next week, which is less than three full months from our initial receipt of the gene sequence from the WHO. We are currently scaling up the process used to manufacture VRP vaccines and anticipate yields up to 1 million doses of pandemic influenza vaccine per lot at the 1,000 L bioreactor scale. Since the process is performed predominantly in disposable equipment, the design, construction and validation of a facility leading to the production of product for the market would be 1-2 years less than for a typical vaccine manufacturing facility."

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. The company's business strategy is to maximize the potential of this platform through a mixture of in-house and partnered programs. The AlphaVax technology is currently being used to advance vaccines for cytomegalovirus, herpes simplex virus, respiratory syncytial virus, a range of cancers, influenza, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP-compliant manufacturing facility is located in Lenoir, NC.


'/>"/>
SOURCE AlphaVax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. AlphaVax Announces Promising Results in Melanoma Studies
2. AlphaVax Continues to Expand the Use of Its Vaccine Platform
3. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
4. AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial
5. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
6. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
7. Elbit Imaging Ltd. Announces - Swiss Team Uses InSightecs ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders
8. Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris
9. Relievant Medsystems Announces Completion of $20 Million Financing
10. Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
11. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... 2017  Life Flight Network and PeaceHealth Oregon Network announced ... care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Life Flight Network work collaboratively to move patients who require ... a time sensitive emergency exists. ...
(Date:7/31/2017)... Tru-D SmartUVC robots have arrived at Brian Allgood Army Community ... for "Total Room Ultraviolet Disinfection," is a 5-foot-5 germ-killing robot that is ... cleans the area with traditional cleaning protocols. ... Tru-D fights germs at Army hospitals ... "Although the BAACH has a very low infection rate, below national ...
(Date:7/27/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... 30, 2017.  The Company reported second quarter net sales ... prior year period, and an increase of 2.1% on ... of contribution from the LDR Holding Corporation acquisition, second ... of 2016, or 0.3% on a constant currency basis. ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... 2017 , ... The Women’s Choice Award, a growing platform that gives a ... Women’s Choice Award. The identification by women of an effective new migraine relief ... are women. In a survey taken by the Women’s Choice Award organization, nine out ...
(Date:8/22/2017)... ... August 22, 2017 , ... GeBBS ... recently the availability of a new professional fee E/M leveling calculator tool. The ... to the healthcare industry. E/M coding is complex which supports the need for ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... of child abuse and neglect, and the struggles faced while hoping for a ... creation of published author, Judy Von Bernewitz, who spent 13 years working with ...
(Date:8/22/2017)... ... ... “Call Of Spiritual Duty”: a revelation in an era defined by intentional confusion. ... up on the streets of North Visalia, California, Carlos Lizarde quickly became familiar with ... to his life, he noticed immediately that opportunities and blessings began to shift in ...
(Date:8/21/2017)... , ... August 21, 2017 , ... ... addition of two plastic surgery fellows for academic year 2017-2018, Christina M. Busuito, ... who have successfully completed residency in Plastic and Reconstructive Surgery. The candidate ...
Breaking Medicine News(10 mins):